Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Downregulation of brain-derived neurotrophic factor (BDNF) and its cognate neurotrophin receptor, TrkB, were observed during the progression of dementia, but whether the Alzheimer's disease (AD) pathological lesions diffuse plaques, (DPs), neuritic plaques (NPs), and neurofibrillary tangles (NFTs) are related to this alteration remains to be clarified. METHODS: Negative binomial (NB) regressions were performed using gene expression data accrued from a single population of CA1 pyramidal neurons and regional hippocampal dissections obtained from participants in the Rush Religious Orders Study (RROS). RESULTS: Downregulation of Bdnf is independently associated with increased entorhinal cortex NPs. Downregulation of TrkB is independently associated with increased entorhinal cortex NFTs and CA1 NPs during the progression of AD. DISCUSSION: Results indicate that BDNF and TrkB dysregulation contribute to AD neuropathology, most notably hippocampal NPs and NFTs. These data suggest attenuating BDNF/TrkB signaling deficits either at the level of BDNF, TrkB, or downstream of TrkB signaling may abrogate NPs and/or NFTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders
Autry, A. E., & Monteggia, L. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005108 · Cited by 1,390
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034
Self-citationBrain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Postsynaptic BDNF‐TrkB signaling in synapse maturation, plasticity, and disease
Yoshii, A., & Constantine‐Paton, M. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20765 · Cited by 744
Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03135.x · Cited by 691
Self-citationBrain-derived neurotrophic factor is associated with age-related decline in hippocampal volume.
Erickson, K. I., Prakash, R. S., Voss, M. W., Chaddock, L., Heo, S., McLaren, M., Pence, B. D., Martin, S. A., Vieira, V. J., Woods, J. A., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.6251-09.2010 · Cited by 604
Regulation of hippocampal synaptic plasticity by BDNF
Leal, G., Afonso, P. M., Salazar, I. L., & Duarte, C. B. (2015) · Brain Research · doi:10.1016/j.brainres.2014.10.019 · Cited by 410
Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity.
Cowansage, K., LeDoux, J., & Monfils, M.-H. (2010) · Current Molecular Pharmacology · doi:10.2174/1874467211003010012 · Cited by 372
Sex differences in Alzheimer’s disease and common neuropathologies of aging
Oveisgharan, S., Arvanitakis, Z., Yu, L., Farfel, J., Schneider, J. A., & Bennett, D. A. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1920-1 · Cited by 330
Overdispersion and Poisson Regression
Berk, R., & MacDonald, J. M. (2008) · Journal of Quantitative Criminology · doi:10.1007/s10940-008-9048-4 · Cited by 299
Neurotrophin signalling: novel insights into mechanisms and pathophysiology
Mitre, M., Mariga, A., & Chao, M. V. (2017) · Clinical Science · doi:10.1042/cs20160044 · Cited by 263
Self-citationNGF and BDNF signaling control amyloidogenic route and Aβ production in hippocampal neurons
Matrone, C., Ciotti, M. T., Mercanti, D., Marolda, R., & Calissano, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806133105 · Cited by 169 · cited 2×
“Rather, a growing number of studies using relevant AD animal and cellular models suggests amyloid-β precursor protein (APP) and its metabolites, including amyloid-β peptide (Aβ) downregulates BDNF expression and BDNF-TrkB retrograde trafficking (Garzon and Fahnestock, 2007; Peng et al., 2009; Poon et al., 2011, 2013),…”
BackgroundCREB expression mediates amyloid β-induced basal BDNF downregulation
Rosa, E., & Fahnestock, M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.014 · Cited by 138 · cited 1×
“Statistically significant results are bolded. through cyclic adenosine monophosphate response element binding protein transcriptional downregulation (Rosa and Fahnestock, 2015).”
BackgroundNeuritic and Diffuse Plaque Associations with Memory in Non-Cognitively Impaired Elderly
Malek-Ahmadi, M., Perez, S. E., Chen, K., & Mufson, E. J. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160365 · Cited by 73
Self-citation
Research works printed but not linked: 76
- Abner, 2017, Outcomes after diagnosis of mild cognitive impairment in a large autopsy series, Ann. Neurol., 81, 549, 10.1002/ana.24903 · DOI · Paper page
- Alldred, 2008, Terminal continuation (TC) RNA amplification enables expression profiling using minute RNA input obtained from mouse brain, Int. J. Mol. Sci., 9, 2091, 10.3390/ijms9112091 · DOI · Paper page
- Alldred, 2009, Terminal continuation (TC) RNA amplification without second strand synthesis, J. Neurosci. Methods, 177, 381, 10.1016/j.jneumeth.2008.10.027 · DOI · Paper page
- Alldred, 2012, Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction, Neurobiol. Dis., 45, 751, 10.1016/j.nbd.2011.10.022 · DOI · Paper page
- Alldred, 2015, Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of down syndrome (DS) and Alzheimer's disease (AD), Brain Struct. Funct., 220, 2983, 10.1007/s00429-014-0839-0 · DOI
- Alldred, 2018, CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of down syndrome and Alzheimer's disease following maternal choline supplementation, Hippocampus, 28, 251, 10.1002/hipo.22832 · DOI · Paper page
- Allen, 2011, The neurotrophins and their role in Alzheimer's disease, Curr. Neuropharmacol., 9, 559, 10.2174/157015911798376190 · DOI · Paper page
- Alvarez, 2014, Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer's disease, J. Alzheimers Dis., 42, 1347, 10.3233/JAD-140849 · DOI
- Arancibia, 2008, Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats, Neurobiol. Dis., 31, 316, 10.1016/j.nbd.2008.05.012 · DOI · Paper page
- Arango-Lievano, 2016, Deletion of neurotrophin signaling through the glucocorticoid receptor pathway causes tau neuropathology, Sci. Rep., 6, 37231, 10.1038/srep37231 · DOI
- Austin, 2015, The number of subjects per variable required in linear regression analyses, J. Clin. Epidemiol., 68, 627, 10.1016/j.jclinepi.2014.12.014 · DOI · Paper page
- Belrose, 2014, Increased pro-nerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies, Neurobiol. Aging, 35, 926, 10.1016/j.neurobiolaging.2013.08.029 · DOI · Paper page
- Bennett, 2012, Longitudinal epidemiologic clinical-pathologic studies of aging and Alzheimer's disease, Curr. Alzheimer Res., 9, 617
- Bennett, 2002, Natural history of mild cognitive impairment in older persons, Neurology, 59, 198, 10.1212/WNL.59.2.198 · DOI · Paper page
- Bennett, 2012, Overview and findings from the religious orders study, Curr. Alzheimer Res., 9, 628, 10.2174/156720512801322573 · DOI · Paper page
- Burnouf, 2013, NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a tau transgenic model, Aging Cell, 12, 11, 10.1111/acel.12018 · DOI · Paper page
- Che, 2004, Amplification of transcripts using terminal continuation, Lab. Investig., 84, 131, 10.1038/labinvest.3700005 · DOI
- Corsetti, 2008, Identification of a caspase-derived N-terminal tau fragment in cellular and animal Alzheimer's disease models, Mol. Cell. Neurosci., 38, 381, 10.1016/j.mcn.2008.03.011 · DOI
- Counts, 2007, {alpha}7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease, Arch. Neurol., 64, 1771, 10.1001/archneur.64.12.1771 · DOI · Paper page
- Dickson, 2009, Neuropathology of non-Alzheimer degenerative disorders, Int. J. Clin. Exp. Pathol., 3, 1
- Donnelly-Kehoe, 2018, Looking for Alzheimer's disease morphometric signatures using machine learning techniques, J. Neurosci. Methods, 302, 24, 10.1016/j.jneumeth.2017.11.013 · DOI · Paper page
- Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol., 6, 734, 10.1016/S1474-4422(07)70178-3 · DOI · Paper page
- Forlenza, 2015, Lower cerebrospinal fluid concentration of brain-derived neurotrophic factor predicts progression from mild cognitive impairment to Alzheimer's disease, NeuroMolecular Med., 17, 326, 10.1007/s12017-015-8361-y · DOI
- Garzon, 2007, Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells, J. Neurosci., 27, 2628, 10.1523/JNEUROSCI.5053-06.2007 · DOI · Paper page
- Garzon, 2002, A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex, J. Neurochem., 82, 1058, 10.1046/j.1471-4159.2002.01030.x · DOI · Paper page
- Ginsberg, 2005, RNA amplification strategies for small sample populations, Methods, 37, 229, 10.1016/j.ymeth.2005.09.003 · DOI
- Ginsberg, 2008, Transcriptional profiling of small samples in the central nervous system, Methods Mol. Biol., 439, 147, 10.1007/978-1-59745-188-8_10 · DOI · Paper page
- Ginsberg, 2014, Considerations in the use of microarrays for analysis of the CNS, Ref. Module. Biomed Res., 1
- Ginsberg, 2000, Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons, Ann. Neurol., 48, 77, 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.0.CO;2-A · DOI · Paper page
- Ginsberg, 2006, Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease, J. Neurochem., 97, 475, 10.1111/j.1471-4159.2006.03764.x · DOI · Paper page
- Ginsberg, 2010, Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression, Biol. Psychiatry, 68, 885, 10.1016/j.biopsych.2010.05.030 · DOI · Paper page
- Ginsberg, 2011, Upregulation of select Rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease, J. Chem. Neuroanat., 42, 102, 10.1016/j.jchemneu.2011.05.012 · DOI · Paper page
- Ginsberg, 2012, Gene expression levels assessed by CA1 pyramidal neuron and regional hippocampal dissections in Alzheimer's disease, Neurobiol. Dis., 45, 99, 10.1016/j.nbd.2011.07.013 · DOI · Paper page
- Ginsberg, 2019, Selective decline of neurotrophin and neurotrophin receptor genes within CA1 pyramidal neurons and hippocampus proper: correlation with cognitive performance and neuropathology in mild cognitive impairment and Alzheimer's disease, Hippocampus, 29, 422, 10.1002/hipo.22802 · DOI · Paper page
- Grassi, 2018, A clinically-translatable machine learning algorithm for the prediction of Alzheimer's disease conversion in individuals with mild and premild cognitive impairment, J. Alzheimers Dis., 61, 1555, 10.3233/JAD-170547 · DOI
- Han, 2012, Functional connectivity variations in mild cognitive impairment: associations with cognitive function, J. Int. Neuropsychol. Soc., 18, 39, 10.1017/S1355617711001299 · DOI · Paper page
- Han, 2015, Mild cognitive impairment is associated with poorer decision-making in community-based older persons, J. Am. Geriatr. Soc., 63, 676, 10.1111/jgs.13346 · DOI · Paper page
- Holsinger, 2000, Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease, Brain Res. Mol. Brain Res., 76, 347, 10.1016/S0169-328X(00)00023-1 · DOI · Paper page
- Iwasaki, 2012, Sendai virus vector-mediated brain-derived neurotrophic factor expression ameliorates memory deficits and synaptic degeneration in a transgenic mouse model of Alzheimer's disease, J. Neurosci. Res., 90, 981, 10.1002/jnr.22830 · DOI
- Jiang, 2018, Nanoformulation of brain-derived neurotrophic factor with target receptor-triggered-release in the central nervous system, Adv. Funct. Mater., 28
- Kim, 2009, Regression models for public health surveillance data: a simulation study, Occup. Environ. Med., 66, 733, 10.1136/oem.2008.042887 · DOI
- Lins, 2017, Using artificial neural networks to select the parameters for the prognostic of mild cognitive impairment and dementia in elderly individuals, Comput. Methods Prog. Biomed., 152, 93, 10.1016/j.cmpb.2017.09.013 · DOI
- Malek-Ahmadi, 2018, Cognitive composite score association with Alzheimer's disease plaque and tangle pathology, Alzheimers Res. Ther., 10, 90, 10.1186/s13195-018-0401-z · DOI
- Malek-Ahmadi, 2019, Cerebral amyloid angiopathy and neuritic plaque pathology correlate with cognitive decline in elderly non-demented individuals, J. Alzheimers Dis., 67, 411, 10.3233/JAD-180765 · DOI
- Mariga, 2015, Withdrawal of BDNF from hippocampal cultures leads to changes in genes involved in synaptic function, Dev. Neurobiol., 75, 173, 10.1002/dneu.22216 · DOI · Paper page
- Mazzaro, 2016, Tau-driven neuronal and neurotrophic dysfunction in a mouse model of early tauopathy, J. Neurosci., 36, 2086, 10.1523/JNEUROSCI.0774-15.2016 · DOI
- Michalski, 2015, Brain-derived neurotrophic factor and TrkB expression in the "oldest-old," the 90+ study: correlation with cognitive status and levels of soluble amyloid-beta, Neurobiol. Aging, 36, 3130, 10.1016/j.neurobiolaging.2015.08.022 · DOI · Paper page
- Mirra, 1991, The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease, Neurology, 41, 479, 10.1212/WNL.41.4.479 · DOI · Paper page
- Mitra, 2019, Innovative therapy for Alzheimer's disease-with focus on biodelivery of NGF, Front. Neurosci., 13, 38, 10.3389/fnins.2019.00038 · DOI · Paper page
- Mufson, 1999, Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment, Exp. Neurol., 158, 469, 10.1006/exnr.1999.7086 · DOI · Paper page
- Mufson, 2000, Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease, J. Comp. Neurol., 427, 19, 10.1002/1096-9861(20001106)427:1<19::AID-CNE2>3.0.CO;2-A · DOI
- Mufson, 2002, Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease, Neurochem. Res., 27, 1035, 10.1023/A:1020952704398 · DOI
- Mufson, 2002, Loss of basal forebrain p75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease, J. Comp. Neurol., 443, 136, 10.1002/cne.10122 · DOI · Paper page
- Mufson, 2007, Cholinotrophic molecular substrates of mild cognitive impairment in the elderly, Curr. Alzheimer Res., 4, 340, 10.2174/156720507781788855 · DOI · Paper page
- Mufson, 2012, Mild cognitive impairment: pathology and mechanisms, Acta Neuropathol., 123, 13, 10.1007/s00401-011-0884-1 · DOI · Paper page
- Mufson, 2015, Hippocampal plasticity during the progression of Alzheimer's disease, Neuroscience, 309, 51, 10.1016/j.neuroscience.2015.03.006 · DOI · Paper page
- Mufson, 2016, Molecular and cellular pathophysiology of preclinical Alzheimer's disease, Behav. Brain Res., 311, 54, 10.1016/j.bbr.2016.05.030 · DOI · Paper page
- Mufson, 2016, Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment, Neurobiol. Aging, 37, 147, 10.1016/j.neurobiolaging.2015.10.012 · DOI · Paper page
- Murray, 1994, Differential regulation of brain-derived neurotrophic factor and type II calcium/calmodulin-dependent protein kinase messenger RNA expression in Alzheimer's disease, Neuroscience, 60, 37, 10.1016/0306-4522(94)90202-X · DOI
- Nagahara, 2013, Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice, J. Neurosci., 33, 15596, 10.1523/JNEUROSCI.5195-12.2013 · DOI · Paper page
- Naito, 2017, Emerging roles of the neurotrophin receptor TrkC in synapse organization, Neurosci. Res., 116, 10, 10.1016/j.neures.2016.09.009 · DOI
- Peng, 2009, Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease, J. Neurosci., 29, 9321, 10.1523/JNEUROSCI.4736-08.2009 · DOI · Paper page
- Phillips, 1991, BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease, Neuron., 7, 695, 10.1016/0896-6273(91)90273-3 · DOI · Paper page
- Poon, 2011, Beta-amyloid impairs axonal BDNF retrograde trafficking, Neurobiol. Aging, 32, 821, 10.1016/j.neurobiolaging.2009.05.012 · DOI · Paper page
- Poon, 2013, Beta-amyloid (Abeta) oligomers impair brain-derived neurotrophic factor retrograde trafficking by down-regulating ubiquitin C-terminal hydrolase, UCH-L1, J. Biol. Chem., 288, 16937, 10.1074/jbc.M113.463711 · DOI · Paper page
- Rajagopal, 2004, Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes, J. Neurosci., 24, 6650, 10.1523/JNEUROSCI.0010-04.2004 · DOI · Paper page
- Rosa, 2016, Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease, Neurobiol. Aging, 48, 135, 10.1016/j.neurobiolaging.2016.08.020 · DOI · Paper page
- Sen, 2017, ApoE isoforms differentially regulates cleavage and secretion of BDNF, Mol. Brain., 10, 19, 10.1186/s13041-017-0301-3 · DOI · Paper page
- Signaevsky, 2019, Artificial intelligence in neuropathology: deep learning-based assessment of tauopathy, Lab. Invest., 99, 1019, 10.1038/s41374-019-0202-4 · DOI · Paper page
- Skaper, 2008, The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors, CNS Neurol. Disord. Drug Targets, 7, 46, 10.2174/187152708783885174 · DOI · Paper page
- Tanila, 2017, The role of BDNF in Alzheimer's disease, Neurobiol. Dis., 97, 114, 10.1016/j.nbd.2016.05.008 · DOI · Paper page
- Tapia-Arancibia, 2008, New insights into brain BDNF function in normal aging and Alzheimer disease, Brain Res. Rev., 59, 201, 10.1016/j.brainresrev.2008.07.007 · DOI · Paper page
- Thompson Ray, 2011, Decreased BDNF, TrkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders, J. Psychiatry Neurosci., 36, 195, 10.1503/jpn.100048 · DOI · Paper page
- Tiernan, 2016, Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease, Neurobiol. Aging, 42, 80, 10.1016/j.neurobiolaging.2016.02.031 · DOI · Paper page
- Tjur, 1998, Nonlinear regression, quasi likelihood, and overdispersion in generalized linear models, Am. Stat., 52, 222, 10.1080/00031305.1998.10480567 · DOI · Paper page
- Yu, 2019, Association of cortical beta-amyloid protein in the absence of insoluble deposits with alzheimer disease, JAMA Neurol., 10.1001/jamaneurol.2019.0834 · DOI
Cited by
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
Lei, A. A., Phang, V. W. X., Lee, Y. Z., Kow, A. S. F., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072940 · Cited by 207
“The hippocampus, responsible for memory storage and processing, endures decreases in neuroprotective factors, including brain-derived neurotrophic factor (BDNF) expression and signalling, under chronic stress, which compromises neuronal plasticity [101,102].”
The Alzheimer’s gene SORL1 is a regulator of endosomal traffic and recycling in human neurons
Mishra, S., Knupp, A., Szabo, M. P., Williams, C. A., Kinoshita, C., Hailey, D. W., Wang, Y., Andersen, O. M., & Young, J. E. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04182-9 · Cited by 126
Eggert, S., Kins, S., Endres, K., & Brigadski, T. (2022) · Biological Chemistry · doi:10.1515/hsz-2021-0330 · Cited by 46
“Furthermore, the inverse correlation between BDNF, its receptor TrkB, β -amyloidosis (A β plaques), and neuro-fi brillary tangles within speci fi c regions of postmortem tissue strengthen the link between pathological features of AD and BDNF signaling (Ginsberg et al. 2019b).”
BackgroundFinding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease
Salasova, A., Monti, G., Andersen, O. M., & Nykjaer, A. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00576-2 · Cited by 42
Metadata
- Authors
- Ginsberg, S. D., Malek-Ahmadi, M. H., Alldred, M. J., Chen, Y., Chen, K., Chao, M. V., Counts, S. E., & Mufson, E. J.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 132
- Pages
- 104540
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2964134247
- Cited by
- 70
- References
- 16
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging
- Alzheimer's Association
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.